CARGO Therapeutics, Inc. Common Stock (CRGX) NASDAQ
4.47
+0(+0.00%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
4.47
+0(+0.00%)
Currency In USD
| Previous Close | 4.47 |
| Open | 4.47 |
| Day High | 4.47 |
| Day Low | 4.47 |
| 52-Week High | 25.45 |
| 52-Week Low | 3 |
| Volume | 9.53M |
| Average Volume | 1.68M |
| Market Cap | 216.19M |
| PE | -0.97 |
| EPS | -4.62 |
| Moving Average 50 Days | 4.45 |
| Moving Average 200 Days | 7.81 |
| Change | 0 |
Data not available
CARGO Therapeutics Enters into Agreement to Be Acquired by Concentra Biosciences for $4.379 in Cash per Share Plus a Contingent Value Right
GlobeNewswire Inc.
Jul 08, 2025 10:00 AM GMT
SAN CARLOS, Calif., July 08, 2025 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc. (“CARGO” or the “Company”) (NASDAQ: CRGX), a biotechnology company that has focused on developing CAR T-cell therapies, today announced that it has entered into a defini
CARGO Therapeutics Provides Corporate Update
GlobeNewswire Inc.
Mar 18, 2025 8:05 PM GMT
- Development of CRG-023 and allogeneic platform suspended; further reduction in force (RIF) of approximately 90% to preserve cash and maximize shareholder value - - CARGO had cash, cash equivalents and marketable securities of $368.1 million as of D
CARGO Therapeutics to Discontinue FIRCE-1 Phase 2 Study of Firi-cel; Advances Remaining Programs While Evaluating Strategic Options
GlobeNewswire Inc.
Jan 29, 2025 9:05 PM GMT
CARGO elects to discontinue FIRCE-1, a Phase 2 clinical study of firicabtagene autoleucel (firi-cel)1; Company believes results do not support a competitive benefit-risk profile for patients.CARGO to implement a workforce reduction of approximately 5